Clinical, laboratory and hemostatic assessment of canine patients with parvovirus, associated or not with bacteremia

• Grant number: 25/00484-5
• Support Opportunities: Scholarships in Brazil - Master
• Start date: June 01, 2025
• End date: February 28, 2027
• Field of knowledge: Agronomical Sciences - Veterinary Medicine
• Principal Investigator: Regina Kiomi Takahira
• Grantee: Giovanna Valverde Magalhães Barbosa
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Canine parvovirus is distributed worldwide and mainly affects puppies. The occurrence of bacterial translocation and systemic complications makes it a recognized experimental model for bacteremia and sepsis. In some regions of Brazil, the prevalence of canine parvovirosis can exceed 50%, however, studies evaluating the hemostatic profile in dogs with parvovirosis are limited. Conventional hemostasis tests are capable of assessing states of hypocoagulability. Thromboelastometry, on the other hand, is a useful tool for diagnosing states of hypercoagulability or hypocoagulability, conditions described in dogs with sepsis. With this in mind, this study aims to evaluate the hemostatic profile of dogs with parvovirus during the course of the disease, as well as to identify possible prognostic indicators and assess the hemostatic differences between dogs with canine parvovirus in sepsis and those that have not entered sepsis. To this end, 60 dogs divided into two groups will be assessed: 30 clinically healthy dogs (control group), assessed at a single point in time, and 30 dogs with positive PCR for canine parvovirus, assessed at three different points in time. Based on the laboratory results and clinical parameters, the animals in the sick group will be classified as septic or non-septic, as well as with or without disseminated intravascular coagulation (DIC). In addition, the paediatric Glasgow Scale will be applied, and blood culture, culture and mass spectrometry will be carried out to confirm the diagnosis of the bacterial species, using the MALDI-TOF MS¿ device, an in vitro microbial sensitivity profile of the isolates and Bac 16S PCR to characterize the bacteremia. Variables will be compared between the time points, as well as between the groups according to: survival, clinical severity (Glasgow Scale) and the bacterial genus involved. (AU)